HIV testing Market Size, Share, Growth, and Industry Analysis, By Type ( Saliva,Blood,Other ), By Application ( Hospital,Clinic,Home care environment,other ), Regional Insights and Forecast to 2035

HIV testing Market Overview

The global HIV testing Market size estimated at USD 2768.11 million in 2026 and is projected to reach USD 4655.08 million by 2035, growing at a CAGR of 7.71% from 2026 to 2035.

The global HIV testing Market continues to evolve as the demand for early and rapid diagnosis increases. In 2024, approximately 40.8 million people globally were living with HIV, with about 1.3 million new infections reported in the same year, driving expansion of HIV testing solutions worldwide. Over 20 million HIV self‑testing kits were distributed globally in 2023, highlighting rapid adoption of decentralized testing methods across diverse regions. Blood‑based kits accounted for approximately 54% share of HIV testing devices, while saliva‑based kits held nearly 45% share, indicating broad diversification in test modalities. Regional market share data shows North America dominating with over 33% share of HIV testing Market penetration, followed by Europe with more than 25% share and Asia‑Pacific with close to 24% share of the industry landscape. These figures anchor the HIV testing Market Analysis and HIV testing Industry Report outlook into quantifiable global metrics.

In the USA HIV testing Market, adoption of self‑testing and diagnostics is significantly high. The United States accounted for the largest share of North America’s HIV testing Market in 2024, representing more than 75% of total testing share in the region. Over 30% of high‑risk individuals in the U.S. prefer HIV self‑testing over clinic‑based testing, demonstrating strong consumer preference for privacy and convenience. Approximately 40 million Americans have been tested for HIV at least once, and nearly 1.2 million people in the U.S. are living with HIV, emphasizing the need for continuous expansion of testing infrastructure and services in the country.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 40% of undiagnosed HIV cases globally underscore need for increased testing reach, with rapid tests preferred in 60% of screening programs.
• Major Market Restraint: 35% of markets report limited access to testing facilities in rural areas, restraining market penetration.
• Emerging Trends: 50% of all new test kit distributions in 2023 were saliva‑based or home self‑test formats.
• Regional Leadership: North America maintained a 33%+ share in the global HIV testing Market in 2024.
• Competitive Landscape: Top diagnostic brands constitute approximately 30% share of identifiable market volume.
• Market Segmentation: Blood‑based kits held roughly 54% share and saliva‑based accounted for 45% share in 2024.
• Recent Development: 20 million self‑test kits were distributed globally in 2023, indicating significant expansion of testing adoption.

Latest Trends

In the latest HIV testing Market Trends, blood‑based HIV tests maintained approximately 54 – 56% share of all testing modalities in 2024, with blood fingerstick kits dominant due to higher sensitivity and familiarity among health programs. Saliva‑based kits continue to expand, accounting for about 44 – 45% of all self‑testing kits distributed globally in recent years. The shift toward decentralized testing is evident as online and retail pharmacy distribution channels contributed to nearly 48% share in test accessibility in developed regions. At‑home testing has gained measurable traction, as over 30% of HIV tests in high‑income markets are now self‑initiated without in‑clinic visits. A growing number of countries, exceeding 100 nations, have adopted formal self‑testing policies, supporting the distribution of more than 20 million kits in 2023 alone. In HIV testing Market Analysis, panels of rapid tests delivering results in 15‑20 minutes represent approximately 70% of all point‑of‑care test usage worldwide, further emphasizing demand for swift diagnostics. Digital integration of smartphone apps and telehealth linkage is influencing user experience, with early pilots showing >98% concordance between app‑assisted and professional interpretation results in controlled evaluations.

Market Dynamics

Drivers

Rising demand for fast, accessible HIV testing solutions.

The HIV testing Market Growth is primarily driven by increasing global emphasis on early detection, with more than 40 million people worldwide living with HIV and approximately 1.3 million new infections recorded in 2024 alone. Rapid diagnostic tests, especially saliva‑based and blood fingerstick kits, facilitate fast results in 15‑20 minutes, expanding field and at‑home testing adoption. Over 20 million self‑test kits were distributed globally in 2023, reflecting significant uptake of decentralized testing solutions. Consumer preference for private HIV self‑testing – reported by over 30% of high‑risk individuals in developed markets – underpins strong demand. NGO initiatives in countries such as Kenya and South Africa have reached millions through community outreach, further embedding HIV testing at local levels. Hospital laboratories continue to integrate self‑testing within broader screening programs, with hospitals contributing over 50% of diagnostic test usage in certain regions. Ongoing technological improvements and WHO prequalification policies bolster access to reliable test kits, increasing global testing reach across populations.

Restraints

Limited testing access in low‑resource areas.

One of the key restraints in the HIV testing Market is constrained access to testing infrastructure in underserved regions, affecting more than 35% of rural and low‑income populations worldwide. Despite expanded distribution channels, physical access barriers persist where clinics and laboratories are sparse, resulting in delayed testing and diagnosis. Stigma and lack of awareness continue to limit uptake in many communities, with surveys showing that up to 40% of people at risk may avoid testing due to fear of discrimination. In some regions, blood‑based kits with more than 54% share require professional handling, restricting self‑testing adoption. Limited internet penetration also hinders online ordering of self‑test kits, which make up about 48% of decentralized distribution channels in developed markets. Health systems in low‑income nations often lack the capacity to scale large‑volume testing, delaying integration of rapid diagnostic technologies and digital linkage tools that require supportive infrastructure. These structural and social barriers create ongoing obstacles to achieving universal testing coverage.

Opportunities

Expansion of home and point‑of‑care testing.

The HIV testing Market presents significant opportunities through increased adoption of at‑home self‑testing and point‑of‑care testing solutions. Saliva‑based kits — representing close to 45% share of test modalities — are well‑positioned to attract first‑time testers due to noninvasive sample collection and rapid results. Home testing platforms, enabled by online and retail pharmacy distribution channels accounting for nearly 48% of access routes, offer privacy and convenience that appeal to diverse demographic groups. Integration with smartphones and telehealth services augments opportunities, with pilot programs demonstrating >98% accuracy in app‑guided interpretation of self‑test results. Rural outreach and NGO‑driven distribution programs can further increase testing adoption in underserved regions that represent 35%+ of all areas lacking adequate clinical infrastructure. Partnerships between manufacturers and public health agencies focusing on combo testing kits (e.g., HIV plus syphilis) also expand clinical utility. Growing policy support across more than 100 countries that have adopted self‑testing guidelines enhances regulatory acceptance and market expansion.

Challenges

Variability in test accuracy and user interpretation.

A significant challenge within the HIV testing Market remains the variability in test accuracy and interpretation among different modalities. While blood‑based kits maintain high sensitivity, saliva‑based kits historically show slightly lower detection levels due to differences in antibody titers, with only one WHO‑prequalified oral test dominating the segment in 2024. Rapid at‑home tests can be prone to user error, especially during early infection window periods, which may result in false negatives for up to 5.2 % to 34.5 % of cases with older rapid assays. These issues highlight the need for enhanced training, clear instructions, and quality control, particularly in decentralized environments. Regulatory standards differ across regions, with some markets lacking robust frameworks for digital health linkages and self‑test certification. Ensuring consistent, high‑quality results across the global HIV testing Market requires ongoing innovation in assay design, improved consumer education, and harmonized regulatory oversight to maintain public trust and uptake.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The HIV testing Market is segmented by type and application, highlighting market penetration and adoption trends. By type, Blood-based kits accounted for 54%, Saliva-based kits held 45%, and Other types contributed 1% of total global test distribution in 2024. Blood tests dominate hospital and clinic use, whereas saliva kits are expanding rapidly in home care and community programs. By application, hospitals captured 50% share, clinics contributed 20%, home care environments accounted for 30%, and other community-based programs filled the remaining share. These figures reflect diversified testing solutions catering to clinical, at-home, and community needs globally.

By Type

Blood-Based HIV Tests (54% Share): Blood-based HIV tests dominate the market with 54% of global test volume in 2024. These include fingerstick, venipuncture, and laboratory-confirmed assays, widely adopted in hospitals and clinics. Blood kits are preferred for confirmatory testing due to higher sensitivity and reliability. Hospitals contribute over 50% of total blood test usage, while clinics account for ~20%, ensuring comprehensive diagnostic coverage. Blood tests also maintain regulatory approval across regions, supporting cross-border adoption. Their robust accuracy during the window period enables early detection in high-risk populations, making them central to the HIV testing Market Analysis.

Saliva-Based HIV Tests (45% Share): Saliva-based HIV tests represent approximately 45% share globally in 2024. They are favored for noninvasive, convenient, and rapid self-testing, especially in home care and outreach programs. Online and retail channels facilitated 48% of saliva-based test distribution, enabling access for first-time testers and youth populations. Saliva kits are growing rapidly in Europe, North America, and Asia-Pacific, offering results in 15–20 minutes with reliable accuracy, particularly for p24 antigen detection. NGOs and community programs account for a significant portion of sales in low-resource settings.

Other HIV Test Types (1% Share): Other test types, including urine-based and alternative sample matrices, contribute 1% of the global market in 2024. Adoption is limited due to lower sensitivity and regulatory hurdles. However, pilot programs are exploring their use in decentralized settings. These tests remain in development pipelines, offering incremental growth opportunities.

By Application

Hospital (50% Share): Hospitals dominate HIV testing applications with 50% share in 2024. They provide confirmatory testing, advanced diagnostics, and integration with antiretroviral therapy programs. Hospitals conduct high-volume blood-based tests, covering diverse patient populations, including high-risk and general screening groups.

Clinic (20% Share): Clinics account for approximately 20% share. They deliver point-of-care testing, early screening, and community-focused services. Clinics support both blood and saliva tests, often in targeted HIV prevention programs, increasing regional coverage and outreach efficiency.

Home Care Environment (30% Share): Home care and self-testing environments captured 30% share in developed markets. Saliva-based kits are dominant, providing privacy, convenience, and accessibility for high-risk populations. Online and retail channels account for 48% of distribution, supporting widespread adoption.

Other Applications (<1% Share): Community-based programs, mobile health units, and NGO-led initiatives cover the remaining <1% of testing applications. These settings are vital for reaching rural or underserved populations, especially in Sub-Saharan Africa and select Asia-Pacific regions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook

North America

In North America, the HIV testing Market maintained leadership with over 33% share of global test adoption in 2024, anchoring its position through strong healthcare infrastructure and consumer preference for private testing. The United States dominated regional uptake, representing more than 75% of North America’s share, driven by widespread availability of both hospital‑based and decentralized testing options including self‑testing kits. Data show that over 30% of high‑risk individuals in the U.S. choose at‑home self‑testing over traditional clinic visits, reinforcing high penetration of rapid oral and blood tests. Retail and online distribution channels accounted for nearly 48% of testing access routes in the region, with pharmacies nationwide stocking a variety of HIV test kits. Hospital and clinic settings continue to contribute significant volumes — with hospitals covering half or more of all advanced diagnostics — through confirmatory and integrated screening programs. Insurance coverage and public health campaigns emphasize routine testing, resulting in millions of Americans screened annually. Canada also contributes measurable volume through similar healthcare policies, with self‑testing adoption increasing among urban populations.

Europe

In Europe, the HIV testing Market holds a strong presence with approximately 25%+ share of global testing activities, supported by national healthcare programs and EU‑wide public health initiatives. The United Kingdom reported distribution of over 1 million self‑tests through government‑backed channels since 2020, emphasizing adoption of at‑home diagnostics and digital health integration, especially among key demographics such as MSM (men who have sex with men) and young adults. Germany’s market saw self‑test usage increase by about 30% among men under 40 between 2020 and 2024, with over 80% of urban pharmacies offering self‑test kits. European health agencies actively promote routine testing, leading to high participation rates among at‑risk groups and incorporation of HIV self‑testing into broader sexual health services. Regional regulatory harmonization under CE certification allows cross‑border distribution of test kits, enhancing market efficiency and consumer access. France, Italy, and Spain also show robust HIV testing adoption, with clinics and community health programs driving education and outreach.

Asia‑Pacific

The Asia‑Pacific HIV testing Market accounted for close to 24% share of global testing in 2024, with markets such as China, India, Japan, and Australia contributing significant volumes. Blood‑based HIV test kits remained the largest segment, representing nearly 60% of test types distributed in the region, while saliva‑based kits gained increasing adoption through community health programs. China and India reported rapid scaling of self‑testing initiatives, reaching millions of consumers via online pharmacies and retail channels, with local NGOs playing a pivotal role in education and distribution. Surveys indicate a 25% rise in self‑test interest among Japanese adults aged 18‑30 between 2020 and 2024, highlighting growing acceptance among youth. Government policies in various Asia‑Pacific countries are increasingly supportive of HIV testing, with public health campaigns promoting early diagnosis and linkage to care. Community outreach strategies in high prevalence regions of Southeast Asia have extended testing into remote areas, impacting overall test uptake. Clinics and diagnostic centers in cities provide confirmatory testing for patients identified through decentralized screening, while mobile health units serve rural populations.

Middle East & Africa

In the Middle East & Africa (MEA) region, the HIV testing Market reflects distinct challenges and opportunities as nations respond to varying prevalence rates and healthcare capacities. Sub‑Saharan Africa remains a central focus, with community and NGO‑led HIV testing initiatives expanding in Kenya, South Africa, Malawi, and neighboring countries where HIV prevalence remains high. Large‑scale outreach programs distribute self‑test kits widely, with millions reaching remote communities. Clinics and hospital networks account for substantial volumes of confirmatory testing, often supported by international health partnerships. Self‑testing has grown as a key strategy to close the diagnostic gap, particularly in areas where up to 40% of people with HIV remain undiagnosed due to stigma or limited facility access. Outside Sub‑Saharan Africa, HIV testing adoption in Middle Eastern countries is varied, with urban centers reporting modest increases in test kit availability through pharmacies and private clinics. Collaborative efforts with multilateral organizations promote routine testing and leverage mobile health technologies to boost coverage.

List of Top HIV testing Companies

• Abbott
• Bio-Rad Laboratories
• Shanghai Kehua
• Intech Innovation
• Wantai
• Biomerieux
• F Hoffmann-La Roche
• Zhuhai Livzon
• Beijing kur
• Jinhao
• BD
• Danaher
• Beijing Blue Cross

Top Two Companies with Highest Market Share

• Abbott Laboratories — holds significant position with widespread HIV test kits across clinical and self‑testing segments, estimating high unit distribution share.
• Bio‑Rad Laboratories — known for high‑performance combination tests and broad institutional adoption, commanding strong share in hospital and lab channels.

Investment Analysis and Opportunities

The HIV testing Market presents diversified investment opportunities across public and private sectors, with measurable activity in both product innovation and distribution infrastructure. Investment trends show expanding capital flows into self‑testing technologies, particularly saliva‑based kits that accounted for around 45% share of global test types in 2024. Emerging digital health integrations that pair test kits with smartphone guidance and telehealth referrals have attracted interest, evidenced by pilot data showing greater than 98% accuracy in guided interpretation. The rise of online and retail pharmacy channels, which contributed nearly 48% of decentralized access pathways, underscores expanding e‑commerce influence on HIV testing distribution, presenting opportunities for technology‑enabled logistics and supply chain platforms. Community outreach and NGO partnerships continue to drive high‑density kit deployment in regions with elevated HIV prevalence, such as Sub‑Saharan Africa, creating demand for scalable manufacturing and distribution investment. Hospitals and clinics retain more than 50% share of traditional diagnostic use, indicating that capital allocation toward improved institutional testing capabilities remains vital. Investors may focus on companies with broad portfolios that include both point‑of‑care tests and integrated digital solutions, capturing multiple segments within the HIV testing Market.

New Product Development

Product innovation in the HIV testing Market continues to accelerate, with multiple developments focused on enhancing usability, accuracy, and accessibility. Blood fingerstick kits, which comprised approximately 54% share in 2024, are being optimized with all‑in‑one integrated design kits that combine lancets, buffers, and detection strips to minimize user error. Saliva‑based kits have also evolved, with second‑generation assays incorporating p24 antigen detection to narrow the window period and improve early‑infection detection performance. Smartphone‑linked self‑testing platforms are emerging, allowing users to scan tests with digital guidance and receive supportive telehealth follow‑ups, with early tests showing >98% diagnostic concordance rates in structured evaluations. Manufacturers are also exploring combination diagnostics that bundle HIV screening with tests for syphilis or other co‑infections, increasing clinical utility in resource‑limited contexts. Additionally, molecular‑based point‑of‑care devices are under development to provide high‑sensitivity early infection detection once exclusive to lab settings, broadening functional capabilities in decentralized environments. Continuous R&D efforts aim to improve stability and shelf life of test reagents under diverse climate conditions, facilitating broader distribution, especially in tropical and remote regions.

Five Recent Developments (2023‑2025)

• Distribution of over 20 million HIV self‑test kits globally in 2023 to expand decentralized access.
• Self‑testing adoption increased by ~30% among males under 40 in Germany between 2020 and 2024, indicating strong consumer uptake.
• UK programs distributed ~1 million self‑tests through public health channels since 2020, with continued momentum in 2025.
• Japan reported a 25% increase in interest for self‑testing among adults ages 18‑30 from 2020 to 2024.
• Pilot digital self‑testing platforms recorded >98% concordance between app‑assisted and professional interpretation in trial studies.

Report Coverage

The HIV testing Market Report delivers comprehensive coverage of global and regional test adoption, types, applications, and strategic insights with quantifiable data points. Core coverage includes segmentation by type", where blood‑based kits commanded approximately 54% share and saliva‑based kits held about 45% share in 2024, evidencing diversified adoption across sample formats. The report also analyzes distribution channels, highlighting that nearly 48% of test accessibility originates from online and retail pharmacy outlets, while hospitals and clinics represent over 50% share of institutional diagnostic usage. Regional performance is substantiated with measurable data, with North America capturing 33%+ share, Europe 25%+ share, Asia‑Pacific close to 24% share, and Middle East & Africa showing robust community outreach numbers. Application segmentation is covered with ≥30% home care testing uptake in certain developed markets. Key insights encompass shifts toward digital integration, telehealth linkage, and community health deployment that contribute to evolving HIV testing Market dynamics. The report’s breadth includes mapping of competitive landscapes, delineating top companies responsible for high unit distribution volumes, such as leading diagnostics firms dominating both self testing and institutional channels. Moreover, policy adoption in over 100 countries and widespread NGO programs.

HIV testing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2768.11 Billion in 2026
Market Size Value By	USD 4655.08 Billion by 2035
Growth Rate	CAGR of 7.71% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Saliva Blood Other By Application : Hospital Clinic Home care environment other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample